Company profile for Medicovestor

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Medicovestor Inc. is positioning itself as a pioneering force in the field of cancer treatment, focusing on leveraging the potent capabilities of antibodies to bring about a revolution in therapeutic approaches. The company's mission centers on harnessing the power of antibodies to create revolutionary precision medicines, challenging the conventional boundaries of therapeutics. The commitment to fully unlocking the potential ...
Medicovestor Inc. is positioning itself as a pioneering force in the field of cancer treatment, focusing on leveraging the potent capabilities of antibodies to bring about a revolution in therapeutic approaches. The company's mission centers on harnessing the power of antibodies to create revolutionary precision medicines, challenging the conventional boundaries of therapeutics. The commitment to fully unlocking the potential of antibodies underscores Medicovestor's dedication to pushing the limits of what can be achieved in the realm of biological tools for medical applications.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
17 State Street, 40th Floor, Battery Park, New York, NY 10004, United States
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Clinical Outsourcing

Clinical Outsourcing

Not Confirmed

envelop Contact Supplier

Clinical Outsourcing

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/06/17/3100820/0/en/FDA-Grants-Orphan-Drug-Designation-to-Medicovestor-s-First-in-Class-ADC-for-Pancreatic-Cancer.html

GLOBENEWSWIRE
17 Jun 2025

https://www.globenewswire.com/news-release/2025/06/09/3095948/0/en/Medicovestor-Inc-and-Sanyou-Biopharmaceuticals-Forge-Strategic-Partnership-to-Develop-First-in-Class-Chemoimmunotherapy-Antibody-Drug-Conjugates.html

GLOBENEWSWIRE
09 Jun 2025

https://www.globenewswire.com/news-release/2024/10/28/2970165/0/en/Medicovestor-Inc-Announces-Issuance-Approval-of-3-Patents-by-the-USPTO.html

#N/A
28 Oct 2024

https://www.globenewswire.com/news-release/2024/04/05/2858586/0/en/Medicovestor-Selected-as-Finalist-to-Present-Its-First-in-Class-ADC-Platforms-at-JP-Morgan-Asset-Management-Life-Sciences-Innovation-Summit.html

GLOBENEWSWIRE
05 Apr 2024

https://www.globenewswire.com/news-release/2023/11/20/2783352/0/en/Medicovestor-Inc-announces-the-completion-of-an-oversubscribed-Seed-Financing-round-to-advance-its-novel-Antibody-Drug-Conjugate-ADC-platforms.html

GLOBENEWSWIRE
20 Nov 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty